Regional Raw Drug Repository for AYUSH

Share This

Shri Shripad Yesso Naik, who is the Union Minister for AYUSH as well as Minister of State for Defense, officially launched the Regional Raw Drug Repository which is also known as RDR for ASU&H Medicine in the Southern Plateau Region in the National Institute of Siddha presently via a virtual case. The programme was chaired by Vaidya Rajesh Kotecha who is the Secretary of the AYUSH Ministry.

Regional Raw Drug Repositories are key parts of the Centrally Funded System including its AYUSH National Mission, that plays a significant role in the traditionally used medicinal crops. As a part of the implementation, the Ministry of AYUSH, via the National Board of Medicinal Plants, introduced the creation of the National Raw Drug Repository as well as the Regional Raw Drug Repository. The NMPB has recognised the National Institute of Siddha as that of the propel academy with the Regional Research Institute of Unani Medicine in Chennai as well as the Siddha Central Research Institute in Chennai as the coordinating Institutes.

There seems to be a global revival in the conventional and innovative medical system. In India, people are lucky to always have knowledge of medicine that stretches back upwards of 3000 years and also have deep-rooted social recognition. Ayurveda, Siddha, Unani and medical systems are available to the public section of our community, such as those residing in isolated and inland areas.

Ayush which is also known as Ayurveda Yoga and Naturopathy Unani Sidda Homoeopathy. The Minister for AYUSH Shripad Yesso Naik officially opened the RRDR specifically for Ayush Medicine Systems at just the Siddha National Institute in the state of Tamil Nadu.

The nation has far more than 9K processing units for Ayurveda, Siddha, Unani and Homeopathy.

That being said, the performance of the medications provided by these units is critically dependent on the production process followed and on the main raw materials. The administration has formulated it compulsory for all industrial processes to comply with Good Manufacturing Practices as stated under Schedule T from the Drugs and Cosmetics Act 1940.

However, provided that over 90 per cent of the products under these pharmaceutical structures are plant-based, it is important to ensure the continued availability of high-quality raw materials.